A Emmett
Overview
Explore the profile of A Emmett including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
14
Citations
247
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hanania N, Kalberg C, Yates J, Emmett A, Horstman D, Knobil K
Pulm Pharmacol Ther
. 2004 Dec;
18(1):19-22.
PMID: 15607123
Long-acting beta(2)-agonists (LABAs) are recommended in the management of patients with chronic obstructive pulmonary disease (COPD). Previous studies have demonstrated that the LABA, salmeterol, improves lung function, symptoms and quality...
2.
Calhoun W, Nelson H, Nathan R, Pepsin P, Kalberg C, Emmett A, et al.
Am J Respir Crit Care Med
. 2001 Sep;
164(5):759-63.
PMID: 11549529
The objective of this study was to determine whether initial maintenance therapy for the treatment of inflammation and bronchoconstriction associated with persistent asthma is more effective with a combination product...
3.
FISH J, Israel E, Murray J, Emmett A, Boone R, Yancey S, et al.
Chest
. 2001 Aug;
120(2):423-30.
PMID: 11502639
Study Objectives: Comparison of inhaled salmeterol powder vs oral montelukast treatment in patients with persistent asthma who remained symptomatic while receiving inhaled corticosteroids. Design: Randomized, double-blind, double-dummy, parallel-group, multicenter trials...
4.
ZuWallack R, Mahler D, Reilly D, Church N, Emmett A, Rickard K, et al.
Chest
. 2001 Jun;
119(6):1661-70.
PMID: 11399688
Background: Patients with COPD often require multiple therapies to improve lung function and decrease symptoms and exacerbations. Salmeterol and theophylline are indicated for the treatment of COPD, but the use...
5.
Matz J, Emmett A, Rickard K, Kalberg C
J Allergy Clin Immunol
. 2001 May;
107(5):783-9.
PMID: 11344343
Background: Adding salmeterol to low-dose fluticasone propionate (FP) produces greater improvements in pulmonary function and symptom control than increasing the dose of FP in patients who remain symptomatic with low-dose...
6.
Nelson H, Busse W, Kerwin E, Church N, Emmett A, Rickard K, et al.
J Allergy Clin Immunol
. 2000 Dec;
106(6):1088-95.
PMID: 11112891
Background: Asthma is a disease of chronic inflammation and bronchoconstriction. Inhaled corticosteroids (ICSs) provide important anti-inflammatory treatment but may not provide optimal control of asthma when taken alone. Two therapeutic...
7.
Rosenthal R, Busse W, Kemp J, Baker J, Kalberg C, Emmett A, et al.
Chest
. 1999 Sep;
116(3):595-602.
PMID: 10492259
Study Objectives: To determine the effect of long-term salmeterol aerosol therapy on airway hyperresponsiveness measured by methacholine challenge. Design: Randomized, double-blind, placebo-controlled, multicenter study. Setting: Thirty-one clinical centers in the...
8.
Murray J, Church N, Anderson W, Bernstein D, Wenzel S, Emmett A, et al.
Allergy Asthma Proc
. 1999 Jul;
20(3):173-80.
PMID: 10389550
This randomized, double-blind, parallel, multi-center study was designed to determine whether the addition of salmeterol to existing inhaled corticosteroid therapy provides greater therapeutic benefit than doubling the dose of inhaled...
9.
CONDEMI J, Goldstein S, Kalberg C, Yancey S, Emmett A, Rickard K
Ann Allergy Asthma Immunol
. 1999 May;
82(4):383-9.
PMID: 10227337
Background: Current treatment guidelines define inhaled corticosteroids such as fluticasone propionate (FP) as the cornerstone of anti-inflammatory therapy for asthma. Objective: The objective was to evaluate the efficacy and safety...
10.
Wenzel S, Lumry W, Manning M, Kalberg C, COX F, Emmett A, et al.
Ann Allergy Asthma Immunol
. 1998 Jul;
80(6):463-70.
PMID: 9647268
Background: Salmeterol xinafoate is a long-acting, highly selective, beta2-adrenergic agonist that produces bronchodilation and clinically significant improvement in pulmonary function for up to 12 hours in patients with asthma. Objective:...